Teicoplanin A2
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Teicoplanin A2 is a new glycopeptide antibiotic belonging to the same family as vancomycin. Teicoplanin consists of five major components (A2-1 through A2-5), one hydrolysis component (A3-1), and four minor components (RS-1 through RS-4) [1]. Teicoplanin is isolated from the fermentation broth of Actinoplanes teichomyceticus nov. sp. and has been endowed with outstanding bactericidal activity against grampositive pathogenic bacteria [2].
In vitro: Teicoplanin inhibited cell wall synthesis in Bacillus subtilis, the inhibition is accompanied by an intracellular accumulation of UDP-N-acetyl-muramyl-pentapeptide. In a cell-free system from Bacillus stearothermophilus, treatment with teicoplanin (40 μg/ml) inhibited 50% of peptidoglycan synthesis, and 100 μg/ml teicoplanin totally suppressed peptidoglycan synthesis [2].
In vivo: Following intravenous administration, concentrations of teicoplanin were high in lung and bone tissue and low in fat in relative to those in plasma in patients with normal renal function. Animal data showed high concentrations in most tissues, and particularly high in liver and kidneys [3].
References:
[1] Bernareggi A, Borghi A, Borgonovi M, et al. Teicoplanin metabolism in humans[J]. Antimicrobial agents and chemotherapy, 1992, 36(8): 1744-1749.
[2] S. Somma, L. Gastaldo and A. Corti. Teicoplanin, a new antibiotic from Actinoplanes teichomyceticus nov. sp. Antimicrobial Agents and Chemotherapy 26(6), 917-923 (1984).
[3] Rowland M. Clinical pharmacokinetics of teicoplanin[J]. Clinical pharmacokinetics, 1990, 18(3): 184-209
.
Physical Appearance | A crystalline solid |
Storage | Store at -20°C |
M.Wt | 1709.39 |
Cas No. | 61036-64-4 |
Formula | C78H77Cl2N8O32R |
Synonyms | Teicoplanin; Teichomycin; Targocid; MDL-507 |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
细胞实验 [1]: | |
细胞系 |
嗜热脂肪芽孢杆菌 |
溶解方法 |
在DMSO中的溶解度≤10mg/ml。为了获得更高的浓度,可以将离心管在37℃加热10分钟和/或在超声波浴中震荡一段时间。原液可以在-20℃以下储存几个月。 |
反应条件 |
40 μg/ml~100μg/ml |
应用 |
Teicoplanin对能够合成肽聚糖的嗜热脂肪芽孢杆菌的无细胞系统抑制率为50%时的抑制浓度为40μg/ml,抑制率为100%时的抑制浓度为100 μg/ml;肽聚糖合成的抑制伴随着脂质中间体的平行积累。 |
References: [1]. Somma S, Gastaldo L, Corti A. Teicoplanin, a new antibiotic from Actinoplanes teichomyceticus nov. sp. Antimicrob Agents Chemother. 1984 Dec;26(6):917-23. doi: 10.1128/aac.26.6.917. PMID: 6240963; PMCID: PMC180050. |